Epidemiology and clinical characteristics of elite controllers - PubMed (original) (raw)
Review
Epidemiology and clinical characteristics of elite controllers
Jason F Okulicz et al. Curr Opin HIV AIDS. 2011 May.
Abstract
Purpose of review: Recent studies have been published characterizing the epidemiology of elite controllers. The demographic features, clinical characteristics, and HIV disease outcomes of elite controllers are summarized.
Recent findings: Elite controllers are defined by the ability to spontaneously suppress plasma viremia. Despite differing definitions in the literature, studies have shown that elite control of HIV infection is established soon after seroconversion and occurs in less than 1% of HIV-infected individuals. Elite controllers are demographically heterogeneous with diverse racial backgrounds and modes of HIV transmission, though genetic studies demonstrate an overrepresentation of protective HLA alleles. Elite controllers typically have elevated CD4 cell counts, stable CD4 trajectories, and more favorable clinical outcomes compared with viremic patients. A proportion of elite controllers, however, may experience HIV disease progression with loss of virologic control, CD4 cell declines, and rarely AIDS-defining events.
Summary: Elite controllers are a subgroup of HIV-infected individuals characterized by the ability to spontaneously maintain virologic control. The mechanisms underlying elite control are aggressively being sought to guide vaccine development and novel therapeutic strategies. As elite control may be a temporary state, the ability to distinguish and further characterize elite controllers with long-term clinical success from those with HIV disease progression is of major importance.
Similar articles
- Elite controllers as a model of functional cure.
Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Autran B, et al. Curr Opin HIV AIDS. 2011 May;6(3):181-7. doi: 10.1097/COH.0b013e328345a328. Curr Opin HIV AIDS. 2011. PMID: 21460722 Review. - Unique features of memory T cells in HIV elite controllers: a systems biology perspective.
Fonseca SG, Procopio FA, Goulet JP, Yassine-Diab B, Ancuta P, Sékaly RP. Fonseca SG, et al. Curr Opin HIV AIDS. 2011 May;6(3):188-96. doi: 10.1097/COH.0b013e32834589a1. Curr Opin HIV AIDS. 2011. PMID: 21430529 Review. - How do HIV elite controllers do what they do?
Saag M, Deeks SG. Saag M, et al. Clin Infect Dis. 2010 Jul 15;51(2):239-41. doi: 10.1086/653678. Clin Infect Dis. 2010. PMID: 20550453 No abstract available. - HIV-1 elite controllers: beware of super-infections.
Clerc O, Colombo S, Yerly S, Telenti A, Cavassini M. Clerc O, et al. J Clin Virol. 2010 Apr;47(4):376-8. doi: 10.1016/j.jcv.2010.01.013. Epub 2010 Feb 13. J Clin Virol. 2010. PMID: 20153976 - Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
Bello G, Velasco-de-Castro CA, Bongertz V, Rodrigues CA, Giacoia-Gripp CB, Pilotto JH, Grinsztejn B, Veloso VG, Morgado MG. Bello G, et al. J Med Virol. 2009 Oct;81(10):1681-90. doi: 10.1002/jmv.21565. J Med Virol. 2009. PMID: 19697415
Cited by
- Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act.
Durand CM, Halpern SE, Bowring MG, Bismut GA, Kusemiju OT, Doby B, Fernandez RE, Kirby CS, Ostrander D, Stock PG, Mehta S, Turgeon NA, Wojciechowski D, Huprikar S, Florman S, Ottmann S, Desai NM, Cameron A, Massie AB, Tobian AAR, Redd AD, Segev DL. Durand CM, et al. Am J Transplant. 2018 Oct;18(10):2579-2586. doi: 10.1111/ajt.14993. Epub 2018 Jul 23. Am J Transplant. 2018. PMID: 29947471 Free PMC article. - Demographics and natural history of HIV-1-infected spontaneous controllers of viremia.
Yang OO, Cumberland WG, Escobar R, Liao D, Chew KW. Yang OO, et al. AIDS. 2017 May 15;31(8):1091-1098. doi: 10.1097/QAD.0000000000001443. AIDS. 2017. PMID: 28301422 Free PMC article. - Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses.
Olvera A, Romero-Martin L, Oriol-Tordera B, Rosas-Umbert M, Escribà T, Mothe B, Brander C. Olvera A, et al. Vaccines (Basel). 2024 Mar 7;12(3):279. doi: 10.3390/vaccines12030279. Vaccines (Basel). 2024. PMID: 38543913 Free PMC article. - Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.
Winckelmann AA, Munk-Petersen LV, Rasmussen TA, Melchjorsen J, Hjelholt TJ, Montefiori D, Østergaard L, Søgaard OS, Tolstrup M. Winckelmann AA, et al. PLoS One. 2013 Apr 26;8(4):e62074. doi: 10.1371/journal.pone.0062074. Print 2013. PLoS One. 2013. PMID: 23637967 Free PMC article. Clinical Trial. - Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).
Parikh UM, Kiepiela P, Ganesh S, Gomez K, Horn S, Eskay K, Kelly C, Mensch B, Gorbach P, Soto-Torres L, Ramjee G, Mellors JW; MTN-009 Protocol Team. Parikh UM, et al. PLoS One. 2013 Apr 9;8(4):e59787. doi: 10.1371/journal.pone.0059787. Print 2013. PLoS One. 2013. PMID: 23585827 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials